SRC and cancer: Interestingly, kinases within the MAPK, PI3K/AKT and SRC signalling networks (summarised in Table S3) that are involved in cancer progression and resistance to therapy were among those discriminating responders from non-responders, indicating that these pathways, leading to cancer cell proliferation and survival, are more active in melanoma of responding patients.